Consideration of research on some basic problems of clinical pharmacology

Abstract

Abstract: Clinical pharmacology is a subject to study the interactions and rules between drugs and the body .Principles of clinical pharmacology have made significant progress in many aspects, such as clinical trials, and evaluation of new drugs adverse drug reaction monitoring .Much importance should be attached to the study of common, critical and advanced questions in clinical pharmacology .Besides doing the rou-tine service of clinical pharmacology, exploration on academic research should also be strengthened to provide theoretical support to ensure the safety, effectiveness and rationality of clinical drug application .Study on drug interaction, multidrug resistance, pharmacogenetics, pharmacogenomics, PK/PD model, sex phar-macology, pharmacodynamics and molecular mechanism of drug based on pathological histiocyte of human body have attracted people' s attention.Consideration of research on some basic problems of clinical pharmacology were reviewed in this article .

Key words: clinical pharmacology, basic problems

WEI Wei. Consideration of research on some basic problems of clinical pharmacology[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1081-1085.

References

[1] Liao G, Zhang X, Clark DJ, et al.A genomic “roadmap” to “better” drugs[J] .Drug Metab Rev, 2008, 40(2) :225-239.
[2] Vegter S, Boersma C, Rozenbaum M, et al.Pharmaco-economic evaluations of pharmacogenetic and genomic screening programmes:a systematic review on content and adherence to guidelines[J] .Pharmacoeconomics, 2008, 26(7) :569-587.
[3] Agrawal V, Huang N, Miller WL.Pharmacogenetics of P450 oxidoreductase:effect of sequence variantson activi-ties of CYP1A2 and CYP2C19[J] .Pharmacogenet Genomics, 2008, 18(7) :569-576.
[4] Meletiadis J, Chanock S, Walsh TJ.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents[J] .Pharmacogenomics, 2008, 9(5) :561-584.
[5] Halling J, Weihe P, Brosen K.CYP2D6 polymorphism in relation to tramadol metabolism:a study of faroese patients[J] .Ther Drug Monit, 2008, 30(3) :271-275.
[6] Sharom FJ.ABC multidrug transporters:structure, function and role in chemoresistance[J] .Pharmacogenomics, 2008, 9(1) :105-127.
[7] Brodde OE.Beta1-and beta2-adrenoceptor polymorphisms and cardiovascular diseases[J] .Fundam Clin Pharmacol, 2008, 22(2) :107-125.
[8] Koehn J, Fountoulakis M, Krapfenbauer K.Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance[J] .Infect Disord Drug Targets, 2008, 8(2) :109-118.
[9] Yan F, Jiang Y, Li YM, et al.Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetratai sohy droquinolin derivatives[J] .Biol Pharm Bull, 2008, 31(6) :1258-1264.
[10] Kamata S, Kishimoto T, Kobayashi S, et al.Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas[J] . Histopathology, 2008, 52(6) :747-754.
[11] Potocnik U, Glavac D, Dean M.Common germline MDR1 ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancerswith high micro-satellite instability[J] .Cancer Genet Cytogenet, 2008, 183(1) :28-34.
[12] Ko Y, Malone DC, Skrepnek GH, et al.Prescribers' knowledge of and sources of information for potential drug-drug interactions:a postal survey of US prescribers[J] . Drug Saf, 2008, 31(6) :525-536.
[13] Urichuk L, Prior TI, Dursun S, et al.Metabolism of at-ypical antipsychotics:involvement of cytochrome p450 enzymes and relevance for drug-drug interactions[J] .Curr Drug Metab, 2008, 9(5) :410-418.
[14] Elbarbry FA, Marfleet T, Shoker AS.Drug-drug interac-tionswith immunosuppressive agents:review of the invitro functional assays and role of cytochrome P450 enzymes[J] .Transplantation, 2008, 85(9) :1222-1229.
[15] He YL, Sabo R, Sunkara G, et al.Evaluation of pharma-cokinetic interactions between vildagliptin and digoxin in healthy volunteers[J] .J Clin Pharmacol, 2007, 47(8) : 998-1004.
[16] Hemels ME, Van Noord T, Crijns HJ, et al.Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation[J] .J Am Coll Cardiol, 2006, 48(5) :1001-1009.
[17] Suzuyama N, Katoh M, Takeuchi T, et al.Species differ-ences of inhibitory effects on P-glycoprotein-mediated drug transport[J] .J Pharm Sci, 2007, 96(6) :1609-1618.
[18] Nowack R.Herb-drug interactions in nephrology:docu-mented and theoretical[J] .Clin Nephrol, 2008, 69(5) : 319-325.
[19] Butterweck V, Derendorf H.Potential of pharmacokinetic profiling for detecting herbal interactions with drugs[J] . Clin Pharmacokinet, 2008, 47(6) :383-397.
[20] Baek IH, Yun MH, Yun HY, et al.Pharmacokinetic pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans[J] .Arch Pharm Res, 2008, 31(6) :814-821.
[21] Minto CF, Schnider TW.Contributions of PK PD modeling to intravenous anesthesia[J] .Clin Pharmacol Ther, 2008, 84(1) :27-38.
[22] Scandlyn MJ, Stuart EC, Rosengren RJ.Sex-specific differences in CYP450 isoforms in humans[J] .Expert Opin Drug Metab Toxicol, 2008, 4(4) :413-424.